Zobrazeno 1 - 8
of 8
pro vyhledávání: '"MESH: Daunorubicin"'
Autor:
Stéphanie Herveau, Emeline Cros-Perrial, Delphine Demangel, Lars Petter Jordheim, Michel Dreano, Charles Dumontet, Adriana Plesa, Céline Keime, Julie A. Vendrell
Publikováno v:
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2011, 68 (1), pp.97-105. ⟨10.1007/s00280-010-1458-y⟩
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2011, 68 (1), pp.97-105. ⟨10.1007/s00280-010-1458-y⟩
International audience; PURPOSE: The need for new treatment options for acute myeloid leukemia (AML) is increasing. AS602868 is a novel investigational drug with reported activity on AML cells. METHODS: We studied gene expression profiles in AML blas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7eb33848343429dfa0b58759d862f8b7
https://doi.org/10.1007/s00280-010-1458-y
https://doi.org/10.1007/s00280-010-1458-y
Autor:
Odile Burlet-Schiltz, Bernard Monsarrat, Stéphane Manenti, Marie-Pierre Bousquet-Dubouch, Mariette Matondo, Christian Recher, Sandrine Uttenweiler-Joseph, Bernard Payrastre, Nathalie Gallay
Publikováno v:
Leukemia Research
Leukemia Research, Elsevier, 2010, 34 (4), pp.498-506. ⟨10.1016/j.leukres.2009.09.020⟩
Leukemia Research, Elsevier, 2010, 34 (4), pp.498-506. ⟨10.1016/j.leukres.2009.09.020⟩
International audience; The proteasome plays a critical role in the regulation of many cellular processes, including the cell cycle and tumor growth. The proteasome inhibitor bortezomib has recently been approved for the treatment of relapsed and ref
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15c9c627ffc922f7fa4dfe1b585c758e
https://doi.org/10.1016/j.leukres.2009.09.020
https://doi.org/10.1016/j.leukres.2009.09.020
Autor:
Nassera Aouali, Lahcen Eddabra, Hassan El Btaouri, Claudie Madoulet, Hamid Morjani, Charles Dumontet, Sophie Malagarie-Cazenave
Publikováno v:
Oncology Reports
Oncology Reports, Spandidos Publications, 2011, 25 (4), pp.1161-7. 〈10.3892/or.2011.1180〉
Oncology Reports, Spandidos Publications, 2011, 25 (4), pp.1161-7. ⟨10.3892/or.2011.1180⟩
Oncology Reports, Spandidos Publications, 2011, 25 (4), pp.1161-7. 〈10.3892/or.2011.1180〉
Oncology Reports, Spandidos Publications, 2011, 25 (4), pp.1161-7. ⟨10.3892/or.2011.1180⟩
International audience; The selection pressure for resistance to chemotherapy is accompanied by the enhanced expression of ABC proteins and increased cellular glycosphingolipid content. Thus, a possible connection between glycosphingolipid metabolism
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b3533101879df2b23e9d6bdd90421dc
https://hal.archives-ouvertes.fr/hal-00771766
https://hal.archives-ouvertes.fr/hal-00771766
Autor:
Récher, C., Béné, M. C., Lioure, B., Pigneux, A., Vey, N., Delaunay, J., Luquet, I., Hunault, M., Guyotat, D., Bouscary, D., Fegueux, N., Jourdan, E., Lissandre, S., Escoffre-Barbe, M., Bonmati, C., Randriamalala, E., Guièze, R., Ojeda-Uribe, M., Dreyfus, F., Harousseau, J. L., Cahn, J. Y., Ifrah, N., Guardiola, P., Renseigné, Non
Publikováno v:
Leukemia
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2014, 28 (2), pp.440-3. ⟨10.1038/leu.2013.290⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2014, 28 (2), pp.440-3. ⟨10.1038/leu.2013.290⟩
Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e8c325730ae34202e6d6c4bf1132e67
https://hal.archives-ouvertes.fr/hal-00979453
https://hal.archives-ouvertes.fr/hal-00979453
Autor:
Malfuson, Jean-Valère, Etienne, Anne, Turlure, Pascal, De Revel, Thierry, Thomas, Xavier, Contentin, Nathalie, Terré, Christine, Rigaudeau, Sophie, Bordessoule, Dominique, Vey, Norbert, Gardin, Claude, Dombret, Hervé, Renseigné, Non
Publikováno v:
Haematologica
Haematologica, Ferrata Storti Foundation, 2008, 93 (12), pp.1806-13. ⟨10.3324/haematol.13309⟩
Haematologica, Ferrata Storti Foundation, 2008, 93 (12), pp.1806-13. ⟨10.3324/haematol.13309⟩
International audience; BACKGROUND: There is a need for standardization of treatment decisions in older patients with acute myeloid leukemia. The aim of the present study was to analyze the decisional value of poor risk factors in 416 elderly patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efd280294cbba760e82d49149ad31ae4
https://hal.archives-ouvertes.fr/hal-00453264
https://hal.archives-ouvertes.fr/hal-00453264
Autor:
Pascal Turlure, Dominique Bordessoule, Xavier Thomas, Emmanuel Raffoux, Jean-Henri Bourhis, T. Fagot, Thierry de Revel, Nathalie Contentin, Hervé Dombret, Sylvie Castaigne, Claude Gardin, Cécile Pautas, Mauricette Michallet, Christine Terré, Stéphane de Botton, Oumedaly Reman, Claude Preudhomme, Pierre Fenaux
Publikováno v:
Blood
Blood, American Society of Hematology, 2007, 109 (12), pp.5129-35. ⟨10.1182/blood-2007-02-069666⟩
Blood, American Society of Hematology, 2007, 109 (12), pp.5129-35. ⟨10.1182/blood-2007-02-069666⟩
In elderly patients with acute myeloid leukemia (AML) treated intensively, no best postremission strategy has emerged yet. This clinical trial enrolled 416 patients with AML aged 65 years or older who were considered eligible for standard intensive c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95730447022d4dfb60bb9466e44e44bc
https://hal.archives-ouvertes.fr/hal-00453273
https://hal.archives-ouvertes.fr/hal-00453273
Autor:
Anne Vekhoff, Lionel Ades, Xavier Thomas, Anne-Marie Stoppa, Agnès Guerci, Laurent Degos, Eric Deconinck, Sandrine Meyer-Monard, Pierre Fenaux, Frédéric Maloisel, Emmanuel Raffoux, Hervé Dombret, Stéphane de Botton, Nathalie Fegueux, Christine Chomienne, Arnaud Pigneux, Augustin Ferrant, Thierry Lamy, Sylvie Chevret, Françoise Rigal-Huguet
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2006, 24 (36), pp.5703-10. ⟨10.1200/JCO.2006.08.1596⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2006, 24 (36), pp.5703-10. ⟨10.1200/JCO.2006.08.1596⟩
Purpose Several phase II studies have suggested that cytarabine (AraC) was not required in the treatment of newly diagnosed acute promyelocytic leukemia (APL) patients receiving all-trans-retinoic acid (ATRA), an anthracycline, and maintenance therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::747a3d981583ca7a9c88c8bfc3210362
https://www.hal.inserm.fr/inserm-00473473
https://www.hal.inserm.fr/inserm-00473473
Publikováno v:
Molecular Pharmacology
Molecular Pharmacology, American Society for Pharmacology and Experimental Therapeutics, 2002, 61 (3), pp.516-523. ⟨10.1124/mol.61.3.516⟩
Molecular Pharmacology, American Society for Pharmacology and Experimental Therapeutics, 2002, 61 (3), pp.516-23
Molecular Pharmacology, American Society for Pharmacology and Experimental Therapeutics, 2002, 61 (3), pp.516-523
Molecular Pharmacology, American Society for Pharmacology and Experimental Therapeutics, 2002, 61 (3), pp.516-523. ⟨10.1124/mol.61.3.516⟩
Molecular Pharmacology, American Society for Pharmacology and Experimental Therapeutics, 2002, 61 (3), pp.516-23
Molecular Pharmacology, American Society for Pharmacology and Experimental Therapeutics, 2002, 61 (3), pp.516-523
International audience; Anthracyclines are among the most efficient drugs of cancer chemotherapy, but their use is limited by a significant risk of cardiotoxicity, which is still far from being understood. This study investigates whether impairment o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70477895d70fa4118414917f82a88be8
https://hal.univ-grenoble-alpes.fr/hal-01991902
https://hal.univ-grenoble-alpes.fr/hal-01991902